YMTX Insider Trading (Yumanity Therapeutics)
Insider Ownership Percentage: 12.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $49,658.94
Yumanity Therapeutics Share Price & Price History
Current Price: $1.65
Price Change: ▼ Price Decrease of -0.01 (-0.60%)
As of 08/12/2022 01:00 AM ET
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Yumanity Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/5/2022 | Richard Peters | CEO | Sell | 4,584 | $1.85 | $8,480.40 | 100,918 |  |
| 6/3/2022 | Devin Whittemore Smith | SVP | Sell | 2,923 | $1.19 | $3,478.37 | 17,077 | |
| 6/3/2022 | Marie Epstein | Insider | Sell | 1,806 | $1.19 | $2,149.14 | 10,859 | |
| 6/3/2022 | Richard Peters | CEO | Sell | 10,206 | $1.19 | $12,145.14 | 105,502 | |
| 3/28/2022 | Richard Peters | CEO | Sell | 10,715 | $1.85 | $19,822.75 | | |
| 2/3/2022 | Paulash Mohsen | Insider | Sell | 1,958 | $1.83 | $3,583.14 | | |
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Yumanity Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/13/2022 | Renaissance Technologies LLC | 70,508 | $0.13M | 0.0% | +16.7% | 0.649% |  |
| 8/12/2022 | Ikarian Capital LLC | 104,392 | $0.19M | 0.0% | -55.8% | 0.962% | |
| 8/1/2022 | Monaco Asset Management SAM | 50,000 | $91K | 0.0% | N/A | 0.461% | |
| 5/17/2022 | Jane Street Group LLC | 23,040 | $35K | 0.0% | N/A | 0.212% | |
| 5/13/2022 | Renaissance Technologies LLC | 60,408 | $91K | 0.0% | -37.4% | 0.557% | |
| 5/12/2022 | Acadian Asset Management LLC | 61,965 | $91K | 0.0% | -18.4% | 0.571% | |
| 2/10/2022 | Acadian Asset Management LLC | 75,928 | $0.22M | 0.0% | +272.7% | 0.737% | |
| 11/17/2021 | Altium Capital Management LP | 196,000 | $2.02M | 0.5% | +58.5% | 1.902% | |
| 11/16/2021 | Bain Capital Public Equity Management II LLC | 27,972 | $0.29M | 0.0% | -8.3% | 0.271% | |
| 11/15/2021 | Sphera Funds Management LTD. | 75,836 | $0.78M | 0.1% | -34.2% | 0.736% | |
| 11/15/2021 | Ovata Capital Management Ltd | 18,700 | $0.19M | 0.1% | N/A | 0.181% | |
| 11/15/2021 | Ensign Peak Advisors Inc | 33,840 | $0.35M | 0.0% | N/A | 0.328% | |
| 11/12/2021 | Renaissance Technologies LLC | 35,919 | $0.37M | 0.0% | N/A | 0.349% | |
| 11/12/2021 | Stonepine Capital Management LLC | 481,692 | $4.97M | 2.3% | +9.0% | 4.674% | |
| 11/12/2021 | Jump Financial LLC | 10,300 | $0.11M | 0.0% | N/A | 0.100% | |
| 11/9/2021 | BlackRock Inc. | 69,905 | $0.72M | 0.0% | +6.9% | 0.678% | |
| 8/17/2021 | Sphera Funds Management LTD. | 115,298 | $1.34M | 0.1% | -44.7% | 1.130% | |
| 8/17/2021 | Boothbay Fund Management LLC | 304,475 | $0.17M | 0.0% | +2,000.1% | 2.984% | |
| 8/16/2021 | Redmile Group LLC | 59,487 | $0.69M | 0.0% | -90.3% | 0.583% | |
| 8/16/2021 | Diametric Capital LP | 20,939 | $0.24M | 0.2% | N/A | 0.205% | |
| 8/13/2021 | Altium Capital Management LP | 123,693 | $1.44M | 0.3% | +13.8% | 1.212% | |
| 8/13/2021 | Geode Capital Management LLC | 21,024 | $0.24M | 0.0% | +16.1% | 0.206% | |
| 8/5/2021 | GSA Capital Partners LLP | 10,369 | $0.12M | 0.0% | N/A | 0.102% | |
| 5/21/2021 | Citadel Advisors LLC | 47,381 | $43K | 0.0% | N/A | 1.816% | |
| 5/18/2021 | Citadel Advisors LLC | 47,381 | $43K | 0.0% | N/A | 0.000% | |
| 5/17/2021 | Sphera Funds Management LTD. | 208,609 | $3.78M | 0.3% | +59.9% | 0.000% | |
| 5/17/2021 | Ikarian Capital LLC | 219,470 | $3.97M | 0.1% | +65.6% | 0.000% | |
| 5/12/2021 | Geode Capital Management LLC | 18,108 | $0.33M | 0.0% | +9.6% | 0.000% | |
| 5/12/2021 | Pura Vida Investments LLC | 68,853 | $1.25M | 0.0% | N/A | 0.000% | |
| 5/7/2021 | BlackRock Inc. | 64,431 | $1.17M | 0.0% | +18.3% | 0.000% | |
| 2/16/2021 | HarbourVest Partners LLC | 22,030 | $0.38M | 0.1% | N/A | 0.000% | |
| 2/12/2021 | Stonepine Capital Management LLC | 108,847 | $1.85M | 1.4% | N/A | 0.000% | |
| 2/12/2021 | Ikarian Capital LLC | 132,514 | $2.25M | 0.1% | N/A | 0.000% | |
| 2/11/2021 | Artal Group S.A. | 217,391 | $3.70M | 0.1% | N/A | 0.000% | |
| 2/10/2021 | Renaissance Technologies LLC | 18,349 | $0.31M | 0.0% | N/A | 0.000% | |
| 2/9/2021 | Wells Fargo & Company MN | 2,898 | $50K | 0.0% | N/A | 0.000% | |
| 2/5/2021 | BlackRock Inc. | 54,469 | $0.93M | 0.0% | N/A | 0.000% | |
Data available starting January 2016
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Read More on Yumanity Therapeutics
Volume
50,888 shs
Average Volume
46,071 shs
Market Capitalization
$17.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.31
Who are the company insiders with the largest holdings of Yumanity Therapeutics?
Who are the major institutional investors of Yumanity Therapeutics?
Which major investors are selling Yumanity Therapeutics stock?
During the previous quarter, YMTX stock was sold by these institutional investors:
- Ikarian Capital LLC
In the last year, company insiders that have sold Yumanity Therapeutics company stock include:
- Richard Peters (CEO)
- Devin Whittemore Smith (SVP)
- Marie Epstein (Insider)
- Paulash Mohsen (Insider)
Learn More investors selling Yumanity Therapeutics stock.
Which major investors are buying Yumanity Therapeutics stock?
During the previous quarter, YMTX stock was acquired by institutional investors including:
- Monaco Asset Management SAM
- Renaissance Technologies LLC
